Goshua, 2,785 patient aspirin late treatment PSM study: 35% lower mortality [p=0.04], 49% higher ventilation [p=0.04], and 45% higher ICU admission [p=0.02] https://c19p.org/goshua
copied to clipboard
Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis
et al., Blood, doi:10.1182/blood-2020-143349
PSM retrospective 2,785 hospitalized patients in the USA, showing lower mortality and higher ventilation and ICU admission with aspirin treatment.
|
risk of death, 35.0% lower, OR 0.65, p = 0.04, treatment 319, control 319, propensity score matching, RR approximated with OR.
|
|
risk of mechanical ventilation, 49.0% higher, OR 1.49, p = 0.04, treatment 319, control 319, propensity score matching, RR approximated with OR.
|
|
risk of ICU admission, 45.0% higher, OR 1.45, p = 0.02, treatment 319, control 319, propensity score matching, RR approximated with OR.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Goshua et al., 11/5/2020, retrospective, USA, North America, peer-reviewed, 15 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.